Vyas Tushar K, Babbar A K, Sharma R K, Misra Ambikanandan
The Maharaja Sayajirao University of Baroda, Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan, Post Box No.51, Vadodara, 390 001, Gujarat, India.
J Drug Target. 2005 Jun;13(5):317-24. doi: 10.1080/10611860500246217.
The aim of this investigation was to prepare microemulsions containing zolmitriptan (ZT) for rapid drug delivery to the brain to treat acute attacks of migraine and to characterize microemulsions and evaluate biodistribution in rats. Zolmitriptan microemulsions (ZME) were prepared using the titration method and were characterized for globule size distribution and zeta potential. ZT was radiolabeled using (99m)Tc (technetium) and radiolabeled-drug formulations of ZT were used to carry out biodistribution of drug in the brain of Swiss albino rats after intranasal and intravenous administration. The pharmacokinetic parameters, drug targeting efficiency (%DTE) and direct nose-to-brain drug transport (%DTP) were calculated. Brain scintigraphy imaging in rats were also performed to ascertain the uptake of drug into the brain. ZME were transparent and stable with mean globule size of 35 +/- 25 nm and zeta potential of - 38- - 52 mV. (99m)Tc-labeled-drug formulations of ZT were found to be stable and suitable to perform in vivo studies. Following intranasal administrations of zolmitriptan mucoadhesive microemulsion (ZMME), ZME, Zolmitriptan solution (ZS) and intravenous administration of ZS, brain/blood uptake ratios at 0.50 h were found to be 0.70, 0.56, 0.27 and 0.13, respectively, indicating effective brain-targeting following intranasal administration of ZMME. Comparing intranasal administration of ZMME with intravenous administration of ZME, the %DTE and %DTP were found higher indicating effective drug transport following intranasal administration and highest brain-targeting following ZMME administration. Rat brain scintigrams showed substantial uptake of drug into the brain after intranasal administration of ZMME. Studies of this investigation conclusively demonstrated rapid and larger extent of transport into the rat brain following intranasal administration of ZMME and can play a promising role in the treatment of acute attacks of migraine.
本研究的目的是制备含佐米曲普坦(ZT)的微乳剂,以实现药物快速递送至脑内,用于治疗偏头痛急性发作,并对微乳剂进行表征,评估其在大鼠体内的生物分布。采用滴定法制备佐米曲普坦微乳剂(ZME),并对其粒径分布和zeta电位进行表征。用(99m)Tc(锝)对ZT进行放射性标记,使用放射性标记药物制剂在瑞士白化大鼠经鼻和静脉给药后进行药物在脑内的生物分布研究。计算药代动力学参数、药物靶向效率(%DTE)和直接鼻脑药物转运率(%DTP)。还对大鼠进行脑闪烁显像,以确定药物在脑内的摄取情况。ZME呈透明且稳定,平均粒径为35±25nm,zeta电位为-38至-52mV。发现(99m)Tc标记的ZT药物制剂稳定,适合进行体内研究。在经鼻给予佐米曲普坦黏膜黏附微乳剂(ZMME)、ZME、佐米曲普坦溶液(ZS)以及静脉给予ZS后,0.50小时时脑/血摄取比分别为0.70、0.56、0.27和0.13,表明经鼻给予ZMME后脑靶向效果良好。将经鼻给予ZMME与静脉给予ZME进行比较,发现%DTE和%DTP更高,表明经鼻给药后药物转运有效,且ZMME给药后脑靶向性最高。大鼠脑闪烁显像显示经鼻给予ZMME后药物大量摄取入脑。本研究结果确凿地证明,经鼻给予ZMME后药物快速且大量地转运至大鼠脑内,在偏头痛急性发作的治疗中可发挥有前景的作用。